Sera Prognostics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. The company develops and commercializes pregnancy-related biomarker tests and analytics, with PreTRM as its first commercial product. This unaudited report covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. PreTRM is intended to predict preterm-birth risk. The company reported no revenue in the quarter.
Financial highlights
Amounts are in millions of dollars, except per-share data.
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $0.0 | $0.1 |
| Operating expenses | $9.1 | $11.4 |
| Operating loss | $9.1 | $11.3 |
| Other income, net | $1.0 | $0.8 |
| Net loss | $8.1 | $10.6 |
| Net loss per share, basic and diluted | $0.25 | $0.34 |
| Cash from (used in) operating activities | $5.0 | $(4.9) |
| Cash and cash equivalents | $4.2 | $3.9 at Dec. 31, 2023 |
| Marketable securities | $81.1 | $76.0 at Dec. 31, 2023 |
| Total cash, cash equivalents and securities | $85.4 | $79.9 at Dec. 31, 2023 |
| Total assets | $89.9 | $95.4 at Dec. 31, 2023 |
| Total liabilities | $25.1 | $25.3 at Dec. 31, 2023 |
Margins and debt. With no revenue in Q1 2024, a revenue-based margin is not meaningful. Cost of revenue was $17,000. The filing reports lease obligations, not conventional borrowings: $529,000 of finance lease liabilities and $1.1 million of operating lease liabilities at March 31. Current liabilities totaled $24.6 million, including $20.2 million of deferred revenue.
Cash flow detail. Investing activities used $5.7 million, including $16.2 million of securities purchases, partly offset by $11.3 million of maturities and sales; the company also spent $697,000 on domain names. Financing activities provided $1.1 million, mainly from stock-option exercises. Cash increased by $359,000 during the quarter.
Changes versus the prior comparable period
- Revenue fell from $100,000 to zero. Operating expenses declined $2.3 million (about 20%), and net loss improved by $2.5 million (about 23%).
- Selling and marketing expense declined $1.6 million, primarily due to lower personnel costs and reduced commercial spending as the company refocused on institutional sales. Research and development expense fell $420,000: lower clinical-study and laboratory costs were partly offset by increased research and bioinformatics spending.
- Other income rose $229,000, with higher interest income partly offset by lower investment income.
- Operating cash flow improved to positive $5.0 million, but was substantially affected by an $11.3 million decrease in other receivables. The company says it received $11.2 million from Elevance Health during the quarter related to minimum payments for 2023; those payments had been recorded as deferred revenue. They were not Q1 revenue, and test results are recognized as revenue when delivered.
- Accumulated deficit increased to $255.0 million from $246.9 million at year-end 2023. Stock-based compensation was $1.7 million, versus $1.3 million a year earlier.
Outlook, commentary and risks
- Management expects continued operating losses and negative cash flows for the foreseeable future. It says existing resources are sufficient for at least 12 months from issuance of the financial statements and, based on current operating plans, expects cash runway into 2027. The filing provides no numeric revenue or earnings guidance.
- Management expects R&D expense to decrease slightly in 2024 following the end of PRIME enrollment, and selling and marketing expense to decrease for the year before potentially increasing as early as the second half of 2024. G&A expense could remain consistent or decrease slightly.
- The PRIME study’s enrollment was stopped in December 2023 after the DSMB reported that either co-primary endpoint met interim stopping criteria for statistical significance. The company is analyzing results and preparing a manuscript; final results and publication remain important milestones.
- Commercial progress depends on provider adoption, payer coverage and reimbursement, and evidence from studies. The company identifies customer concentration, including expected reliance on a limited number of customers such as Elevance Health, as a risk. Medicaid programs do not currently reimburse for its tests, according to the filing.
- The FDA’s final rule on laboratory-developed tests was published May 6, 2024, after quarter-end, with an effective date of July 5, 2024 and a phased implementation schedule. The company warns that regulatory requirements, litigation, or legislative changes could add cost, require additional studies or authorization, or affect its ability to market PreTRM.
- The company disclosed that it was ineligible to file new short-form Form S-3 registration statements until June 2024 because of a late Form 8-K filing. It has no credit facility or committed capital sources; future financing may be dilutive or restrictive.
- Available-for-sale securities had $239,000 of unrealized losses at quarter-end, attributed to market and interest-rate fluctuations rather than credit deterioration. A hypothetical 100-basis-point rate increase would have reduced their market value by an estimated $700,000.
- Management concluded disclosure controls were effective as of March 31, 2024. The company reported no material litigation and no material changes in contractual obligations during the quarter.
Important facts for investors to verify
- Whether the PRIME results are finalized and published, and whether the reported interim findings translate into reproducible clinical and economic evidence.
- How much of the $20.2 million deferred-revenue balance is recognized as tests are delivered, and whether Elevance Health or other customers make additional purchases beyond contractual minimums.
- Whether payer coverage, reimbursement and provider adoption improve enough to produce recurring revenue, given zero reported revenue in Q1 2024.
- Whether the stated runway into 2027 remains supported by actual spending, collections, study costs and commercial progress; operating cash flow in Q1 benefited from a large receivables movement.
- How the FDA’s LDT rule, related litigation or legislation affects PreTRM’s regulatory status, costs and continued commercialization.
- Whether the company regained Form S-3 eligibility in June 2024 and whether it needs additional financing despite its reported liquidity.